Clinical studies have demonstrated their safety for overweight and obese adults, especially when combined with healthy lifestyle changes
This association was especially notable among younger patients without proteinuria and those not receiving sulfonylurea, dipeptidyl peptidase-4 inhibitors, or RAAS blockers
Around 10% of people carry genetic variations linked to GLP-1 resistance. These individuals appear to have higher-than-normal levels of the hormone glucagon-like peptide-1 (GLP-1)
In Group B,44/76 (57.9%) had CCM at enrolment, of whom 5(11.4%) improved to normal diastolic function, and 12(27.3%) improved to Grade I LVDD (i.e., 38.7% of CCM had regression) ( P =0.009 for difference in CCM regression in Group A vs B)
Treatment duration depends on your medical indication, individual response, and health goals